Satellos Bioscience (MSLE) Liabilities and Shareholders Equity (2023 - 2026)

Satellos Bioscience (MSLE) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $75.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $75.2 million; the TTM figure through Mar 2026 stood at $159.4 million (changed N/A YoY), while the FY2025 annual figure was $31.9 million, down 38.99% from the prior year.
• Liabilities and Shareholders Equity advanced to $75.2 million in Q1 2026 per MSLE's latest filing, from $31.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $75.2 million in Q1 2026 and bottomed at $31.9 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $48.0 million across 4 years, with a median of $42.4 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 60.64% — and 2025, when it slumped 38.99%.
• Satellos Bioscience's Liabilities and Shareholders Equity stood at $32.5 million in 2023, then soared by 60.64% to $52.3 million in 2024, then slumped by 38.99% to $31.9 million in 2025, then soared by 135.9% to $75.2 million in 2026.
• Business Quant data shows MSLE's Liabilities and Shareholders Equity at $75.2 million in Q1 2026, $31.9 million in Q4 2025, and $52.3 million in Q4 2024.